drugset / Trial / NCT00030771

Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients

NCT00030771 ↗

Phase 3 Completed 232 enrolled Swiss Cancer Institute
RandomizedFactorialOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known if chemotherapy plus radiation therapy is more effective than chemotherapy alone before surgery in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying docetaxel and cisplatin with or without radiation therapy to see how well they work when given before surgery in treating patients with stage IIIA non-small cell lung cancer that has spread to lymph nodes in the chest.

Timeline

Start
2001-04-04
Primary completion
2014-04-09
Completion
2023-09-15

Outcome

Missed primary endpoint

paper Median event-free survival was similar in the two groups at 12·8 months (95% CI 9·7-22·9) in the chemoradiotherapy group and 11·6 months (8·4-15·2) in the chemotherapy group (p=0·67). PMID 26275735 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 100 mg/m2 Intravenous
Subject Docetaxel Small molecule 85 mg/m2 Intravenous

Indications